Publications en collaboration avec des chercheurs de Hospital Universitario de Donostia (12)

2022

  1. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

    Journal of Clinical Investigation, Vol. 132, Núm. 7

2020

  1. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  2. SOX9 promotes tumor progression through the axis BMI1-p21CIP

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

    Critical Care, Vol. 22, Núm. 1

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2014

  1. Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic parkinson disease patients, and healthy controls

    Frontiers in Aging Neuroscience, Vol. 6, Núm. JUL

2012

  1. Molecular method for the characterization of Coxiella burnetii from clinical and environmental samples: Variability of genotypes in Spain

    BMC Microbiology, Vol. 12

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229